Skip to main content

Fulcrum Therapeutics, Inc.

FULC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001680581

In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.

13F holders, Q3 2023

Institutional positions in Fulcrum Therapeutics, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
81
−6 vs. Q2 2023
Shares held
56.4M
+1.13M (+2.0%) vs. Q2 2023
Total value
$250.4M
+$68.0M (+37.3%) vs. Q2 2023
New holders
15
17 more added
Sold out
21
26 more reduced

1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q2 2023: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting FULC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ3 2023: 81 institutions
Q1 2021: 68 institutionsQ2 2021: 67 institutionsQ3 2021: 101 institutionsQ4 2021: 110 institutionsQ1 2022: 108 institutionsQ2 2022: 102 institutionsQ3 2022: 105 institutionsQ4 2022: 110 institutionsQ1 2023: 116 institutionsQ2 2023: 88 institutionsQ3 2023: 81 institutionsQ4 2023: 101 institutionsQ1 2024: 126 institutionsQ2 2024: 121 institutionsQ3 2024: 130 institutionsQ4 2024: 119 institutionsQ1 2025: 117 institutionsQ2 2025: 122 institutionsQ3 2025: 129 institutionsQ4 2025: 172 institutionsQ1 2026: 169 institutionsQ2 2026: 154 institutions
Value heldQ3 2023: $250.4M
Q1 2021: $317.0MQ2 2021: $280.8MQ3 2021: $1.03BQ4 2021: $657.3MQ1 2022: $929.9MQ2 2022: $196.6MQ3 2022: $422.1MQ4 2022: $368.5MQ1 2023: $172.2MQ2 2023: $183.2MQ3 2023: $250.4MQ4 2023: $412.3MQ1 2024: $569.7MQ2 2024: $402.0MQ3 2024: $196.4MQ4 2024: $243.4MQ1 2025: $147.8MQ2 2025: $374.5MQ3 2025: $494.9MQ4 2025: $762.7MQ1 2026: $550.1MQ2 2026: $291.3M
Institutions holding FULC and their total value by quarter
QuarterHoldersValue
Q2 2026154$291.3M
Q1 2026169$550.1M
Q4 2025172$762.7M
Q3 2025129$494.9M
Q2 2025122$374.5M
Q1 2025117$147.8M
Q4 2024119$243.4M
Q3 2024130$196.4M
Q2 2024121$402.0M
Q1 2024126$569.7M
Q4 2023101$412.3M
Q3 202381$250.4M
Q2 202388$183.2M
Q1 2023116$172.2M
Q4 2022110$368.5M
Q3 2022105$422.1M
Q2 2022102$196.6M
Q1 2022108$929.9M
Q4 2021110$657.3M
Q3 2021101$1.03B
Q2 202167$280.8M
Q1 202168$317.0M

Institutions, Q3 2023

Shares, value and share of portfolio for each institution holding Fulcrum Therapeutics, Inc.; share changes are against Q2 2023.

Institutions holding FULC in Q3 2023
InstitutionSharesValue% of portfolioChange in sharesAction
New York State Common Retirement Fund0$00.00%−376−100.0%Sold out
NewSquare Capital LLC0$00.00%−30−100.0%Sold out
Tekla Capital Management LLC––––Not filed